Envision Pharma Group appoints Richard Gorman as President, Strategic Consulting

Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.

Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.

Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.

Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.

Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”  

Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”

Close

From everyone at Envision Pharma Group we wish you a wonderful Holiday Season, and a Happy New Year!

Close

Each year, Medical Affairs (MA) teams demonstrate leadership and value through the annual strategic planning process that aligns all multifunctional MA competencies on common objectives. These objectives support the product and organization, and depend on a focused and cohesive medical strategy. A product or organization’s strategy is the foundation for the year ahead and will serve as guidance for overcoming challenges, taking advantages of opportunities, and filling any scientific or clinical gaps.

Envision team members, Joe Kohles and Leah Williams, were afforded the opportunity to collaborate with industry-leading MA professionals, to create the first in a series of standards and guidance documents for MAPS focused on strategic MA planning for a product, the Medical Affairs Strategic Planning Guide and Template. Included in the template and guide are guidance and recommendations on key components of developing a medical plan – including the situational analysis, medical strategy, tactical/operational planning, and medical plan summary.

To access the Medical Affairs Strategic Planning Guide and Template, please visit the MAPS website via this link.

Close

Envision Pharma Group has collaborated with the Ectodermal Dysplasia Society in order to develop a patient information booklet aimed at children that raises awareness and support for the disorder.

“Everybody’s different: An introduction to Ectodermal Dysplasia” has been designed for children aged 4+, with and without ED, and allows parents and schools to explain the condition in child-friendly terms. It facilitates empathy and gives children the ideas and motivation to then help their peers.

Ectodermal Dysplasias are a group of genetic disorders affecting the development or function of the teeth, hair, nails and sweat glands. As the condition often has obvious physical symptoms, and children need extra support, they can be subject to bullying or exclusion by their peers.

Envision utilised its services in patient-focused content strategy, copywriting, illustration and graphic design to work closely with the charity to co-create the booklets that help children explore visible and invisible differences – as well as thinking about the emotional impact of those variances.

As a result of this collaboration, Envision is now among finalists in the Global Healthcare and Pharma Advertising Awards for the Ectodermal Dysplasia booklet, under a “Health Awareness and Advocacy” category.

Creative Strategy and Content Director Sarah Ings from Envision added, “We have created something that will provide many discussion points for children and their peers. The key to its development was a close relationship and co-creation process with those experienced in the condition. Co-creation is a fundamental part of the development of patient materials, and we are honoured to have been able to work with the charity in this way.”

The Ectodermal Dysplasia Society work together with people who have ED, their families, researchers, health and other professionals to develop and share expertise, increase awareness and understanding, and assist with the day-to-day management of ED.

ED Society CEO Diana Perry commented, “My first approach to Envision was to have an age appropriate children’s leaflet produced to help children explain to their peers the genetic condition they have, but over time this evolved into this fantastic booklet. We are so grateful to Envision for their passion and dedication in creating this, which will not only help children affected by ED but all children who are a little different. It has been a huge pleasure working alongside Envision’s team on this project.”

To access a copy of the patient information material and to find out more, click here.

Close

Blood cancer happens when there is a problem with the development of blood cells. The most common type of blood cancer is lymphoma, and the symptoms are general and often overlooked. There are 2 main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma, and it is important to tell the difference between these as doctors treat them differently

Join us in our mission to raise awareness and share this infographic we have developed via your social media channels, you can use these popular hashtags:

#FightBloodCancer
#lymphoma
#endcancer

Close

Envision Pharma Group has moved into new office space in Horsham and is remodelling its original office in the town to facilitate unprecedented business growth, while offering an enhanced working environment.

Office space at St Mark’s Court in Horsham was acquired which now provides seating and facilities for an extra 73 team members. Envision's Chief People Officer Petra Battersby stated, “Envision is not just a brand, it is a culture each of us embraces. Our continued success is down to our people, we endeavour to give our teams the best environments to work within and to continue to support them along their chosen career path.”

Envision received an award in March at an event that celebrates the fastest-growing companies in Sussex – an accolade it has consistently achieved. This latest expansion shows it to be an exciting time for the business, clients and new talent in the medical affairs arena.

The company currently has 14 offices, five in the UK – Bishop’s Stortford, Horsham, London (Hammersmith), Marlow and Wilmslow; one in Serbia; six in the US – Philadelphia, PA; New York, NY; Southport, CT; Madison, NJ; Stirling, NJ and Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney.

Close

The power of the patient voice is increasing. Patients, enabled by technology, are becoming more and more active in their own care. The healthcare industry model is changing as a result and the pharmaceutical industry needs to respond.

We have prepared a report which looks at the reaction to date, citing information gathered from eyeforpharma in Barcelona, Envision Pharma Groups ongoing research activities in this space and our unique Patient Forum in London earlier this year. Ultimately, it asks what does the future look like for pharma and patients alike? Patient centricity – trend or truth?

Download report Close

Envision’s Dawn Lobban raised the profile of patient involvement in publications during a presentation at the recent 23rd congress of the European Hematology Association (June 14-17, 2018, Stockholm, Sweden).

The session was hosted by the European Patients’ Academy on Therapeutic Innovation (EUPATI), and was attended by around 50 patient representatives from different patient advocacy groups.

Dawn covered the current landscape of patient involvement in publications, and “traps and tips” to inform and support patients considering publishing their research. The audience were clearly engaged with this topic, which covers new ground for EUPATI’s patient education programme.

“I really enjoyed discussing scientific publications with the patient advocates attending EHA! There was a lot of interest from this audience in participating as co-authors on relevant clinical publications, as well as publishing their own data in scientific journals – this will really help to build this important body of evidence.” Dawn Lobban, Envision Pharma Group, ISMPP EU Committee Member 2018.

Dawn attended EHA as part of Envision the Patient, our dedicated strategic framework for patient involvement initiatives. If you would like a copy of the presentation, or to discuss Envision’s patient-focused offerings, please get in touch with the team.

Close

Envision Pharma Group has successfully renewed its certification to International Standard Organization (ISO)/IEC 27001.

Along with completing the ISO re-certification audits, new office locations have been included in addition – so the expanded coverage now comprises Hammersmith, Horsham, Marlow and Wilmslow in the UK; Glastonbury, Madison, Philadelphia, Southport and Stirling in the US; and Sydney in Australia.

ISO 27001 is an internationally recognised information security standard that is certified by an independent certification body, and demonstrates a commitment to prospective and existing clients that their sensitive data is protected and in compliance with pertinent security and privacy regulatory requirements – such as Privacy Shield and GDPR.

Kevin Wheatley, Global Head, Facility and Operations at Envision, commented, “We are delighted to announce we have passed again with a completely clean sweep. This achievement demonstrates Envision’s commitment to information governance and the safeguarding of our clients’ data. A big thank you goes to everyone involved in the process.”

ISO develops standards that are accepted as pre-eminent in over 140 countries, including the USA, Australia, Japan and the UK. These standards facilitate international exchange of goods and services, support sustainable and equitable economic growth, promote innovation and protect health, safety and the environment.

By attaining this certification, Envision has demonstrated a clear commitment to Information Security Management to third-parties and stakeholders, facilitating a process and framework to ensure the fulfilment of commercial, contractual and legal responsibilities, and providing for a common security approach within the Envision business units and a formal basis for interoperability between Envision and its customers.

Close

What hot topics are at the forefront of our minds as we approach the half-way post in 2018?

You won't get far in any conversation in pharma before the subject of patient centricity or digital transformation pops up. The landscape is changing but is pharma? We’ve prepared three infographics to review the trends and consider what the future holds…

Healthcare in 2018 – The technology revolution!

Healthcare in 2018 – The power of the patient voice.

Healthcare in 2018 – Time for pharma to re-think its purpose?

Close

Each year, the number of people diagnosed with melanoma increases by 3-7 people per 100. Most melanomas are visible on the skin, so there is a good chance of detecting the disease in its early stages before it has had a chance to grow and spread

Join us in raising awareness by sharing this infographic or THIS VIDEO on your social network, you can use these popular hashtags:

#MelanomaAwareness

#MelanomaAwarenessMonth

#SkinCancer

Download Infographic

Close

Glastonbury, CT, USA, 4 May, 2018 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) has completed the first phase of implementation of the iEnvision medical affairs platform developed by Envision Technology Solutions, part of Envision Pharma Group.

iEnvision is a web-based software platform specifically designed and developed to support multiple medical affairs-related programs of activity. Otsuka is deploying iEnvision to manage several activity types, including Investigator Sponsored Studies, Medical Education, Charitable Contributions, and Client Sponsored Projects (eg, Outcomes Research). Otsuka has also introduced iEnvision to compliantly manage the distribution of publications and medical materials to Otsuka personnel, via the iEnvision Library.

Further planned implementation phases will expand Otsuka’s usage to iEnvision for publications management, converting from Datavision, another Envision product.

Having previously implemented separate solutions, Otsuka sought a single replacement globally-scalable software platform that could provide flexibility and cross-activity coverage. These legacy data sources and systems required amalgamation as part of the implementation management process undertaken by Envision. A master documentation approach was utilized to facilitate data migration, workflow definitions, testing, and configuration.

An internal and external communication program was also developed by Envision’s Operational Excellence unit to introduce, explain, and help accelerate adoption of the Otsuka ‘Medical Affairs Ecosystem’, including program-specific landing pages, system graphics, and user support materials.

“We are pleased to offer external stakeholders a more user-friendly and efficient experience when submitting requests for medical education grants, charitable contributions, and investigator sponsored studies, that will also enable us to respond to requests in a more efficient manner,” said Dusan Kostic, VP, Otsuka Medical Affairs. A staged rollout is now being implemented, which began with US launch for all activities in late 2017, and is progressing to other Otsuka companies in 2018. For the recent Japan launch of one of the modules, translation of the software user interface and support materials to Japanese was undertaken to provide additional ease of use, together with local language training and support offered by Japan-based Envision staff.

Kelli Walker, Envision’s Director of Platform Strategy, and project lead for the Otsuka implementation added, “We are pleased to support Otsuka as they move to a fully integrated global medical affairs program support approach with iEnvision. With iEnvision, Otsuka has implemented a scalable Medical Affairs platform and ‘Ecosystem’ for its companies around the world, providing transparency, tracking, reporting, compliance, and process alignment across multiple activities, with resulting efficiencies offering significant cost savings over time.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving the pharmaceutical, biotechnology, and medical device industries. Envision is a leading provider of evidence communication services and industry-leading technology solutions that have applicability across many areas of Medical Affairs and related functional responsibilities. Envision Pharma Group provides services and technology solutions to more than 80 companies, including 19 of the top 20 pharmaceutical companies.

Envision has 14 offices, five in the UK – Bishop's Stortford, Horsham, London (Hammersmith), Marlow, and Wilmslow; one in Serbia; six in the US – Philadelphia, PA; New York, NY; Southport, CT; Madison, NJ, Stirling, NJ; and Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney. The company employs more than 650 team members, including over 250 highly qualified in-house medical writers and over 140 technology solutions team members involved with software development and customer support.

CONTACT INFORMATION

Kelli Walker, PharmD, MS

Director, Platform Strategy, Envision Technology Solutions

Tel: +1 (215) 239 6605

Email: kelli.walker@envisionpharmagroup.com

www.envisionpharmagroup.com

Close